RxDoctor Payments Data

Elizabeth Albertson, MD

Urology · Rockport, MENPI 1124080445

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $712 of the $877 with a category attached, or 81.2%. 7 manufacturers reported payments, led by AbbVie at 57.5% of the total. Reporting peaked in 2023 at $457 and has fallen 93.3% since, to $31 in 2025. That places this record below the midpoint for urology clinicians in ME, where the typical reported total is $1,024.

$877in general payments, 2019–2025

Across 28 payments — averaging $31.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$504
  • Astellas Pharma US Inc$202
  • Rochester Medical Corporation$58
  • Axonics, Inc.$50
  • Mission Pharmacal Company$28
  • Medtronic$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$71281%
  • Education$16519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)14$504
Astellas Pharma US Inc4$202
Rochester Medical Corporation4$58
Axonics, Inc.2$50
Mission Pharmacal Company2$28
Medtronic1$20
Therapeuticsmd, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$877 in reported general payments places this provider in the 45th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$25,323
Medicare patients
176
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron92$65,983
GemtesaVibegron66$35,259
ElmironPentosan Polysulfate Sodium11$11,374
Tamsulosin Hcl332$3,767
Estradiol50$3,471
Finasteride251$3,426
Methenamine Hippurate33$2,480
Tadalafil14$2,423
Solifenacin Succinate61$2,169
Alfuzosin Hcl ErAlfuzosin Hcl30$922
Silodosin12$896
Oxybutynin Chloride ErOxybutynin Chloride48$666
Tolterodine Tartrate ErTolterodine Tartrate14$576
Cephalexin65$329
Cefdinir13$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$202$65,98392 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 59 urology providers in Maine.

Other urology in Rockport

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →